Description
Reg. No. G2207 (Act 36/1947)
Namibia Reg. No. V97/24.1/828 NS0
NAFDAC Reg. No. 04-3251
Only for use by or under the supervision of persons registered or authorised in terms of section 23 (1) (c) of the Veterinary and Para-Veterinary Professions Act, 1982
(Act 19 of 1982).
Rabies is a controlled disease in terms of the Animal Diseases Act (Act 35 of 1984). The occurrence or suspicion of this disease must be reported to the responsible State Veterinarian immediately.
INDICATIONS
For the active immunisation of healthy dogs, cats, cattle, sheep, goats, ferrets, foxes and horses, and in principle all healthy mammals against rabies. Nobivac® Rabies may be used to reconstitute the freeze-dried canine vaccines, Nobivac® DHP (G2201) and Nobivac® DHPPi (G2377) and may be administered in combination with Nobivac® Lepto (G2200) or Nobivac® L6 (G4482). Vaccination leads to a high peak level within 3 weeks, followed by a more or less constant level, sufficiently high to provide protection.
IMMUNITY
In dogs, peak antibody titres have been demonstrated to occur by 3 weeks after vaccination.
COMPOSITION
Nobivac® Rabies is an inactivated culture of rabies virus, cloned out of strain Pasteur RIV. The virus is grown on the BHK-21 clone CT cell-line and inactivated with β-Propiolactone. It is presented as an aqueous aluminium phosphate suspension.
Each 1 dose of 1 mℓ contains: Inactivated rabies antigen suspension with a potency per dose of ≥ 2,0 i.u. (Ph. Eur. method) with 0,3 % aluminium phosphate as adjuvant, glycine as a buffer and 0,1 % thiomersal as preservative.
